Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
Andrea Marino,
Edoardo Campanella,
Stefano Stracquadanio,
Maddalena Calvo,
Giuseppe Migliorisi,
Alice Nicolosi,
Federica Cosentino,
Stefano Marletta,
Serena Spampinato,
Pamela Prestifilippo,
Stefania Stefani,
Bruno Cacopardo,
Giuseppe Nunnari
Affiliations
Andrea Marino
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
Edoardo Campanella
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy
Stefano Stracquadanio
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
Maddalena Calvo
U.O.C. Laboratory Analysis Unit, A.O.U. “Policlinico-Vittorio Emanuele”, Via S. Sofia 78, 95123 Catania, Italy
Giuseppe Migliorisi
U.O.C. Laboratory Analysis Unit, A.O.U. “Policlinico-Vittorio Emanuele”, Via S. Sofia 78, 95123 Catania, Italy
Alice Nicolosi
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
Federica Cosentino
Unit of Infectious Diseases, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy
Stefano Marletta
Department of Diagnostic and Public Health, Section of Pathology, University of Verona, 37124 Verona, Italy
Serena Spampinato
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy
Pamela Prestifilippo
Intensive Care Unit, ARNAS Garibaldi Hospital, 95122 Catania, Italy
Stefania Stefani
Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy
Bruno Cacopardo
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
Giuseppe Nunnari
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy
This comprehensive review examines the unique attributes, distinctions, and clinical implications of ceftazidime–avibactam (CAZ-AVI) and meropenem–vaborbactam (MEM-VAB) against difficult-to-treat Enterobacterales infections. Our manuscript explores these antibiotics’ pharmacokinetic and pharmacodynamic properties, antimicrobial activities, in vitro susceptibility testing, and clinical data. Moreover, it includes a meticulous examination of comparative clinical and microbiological studies, assessed and presented to provide clarity in making informed treatment choices for clinicians. Finally, we propose an expert opinion from a microbiological and a clinical point of view about their use in appropriate clinical settings. This is the first review aiming to provide healthcare professionals with valuable insights for making informed treatment decisions when combating carbapenem-resistant pathogens.
